Ceruloplasmin prevents hemostatic disorders during experimental hyperammonemia.
Experimental hyperammonemia in rats was accompanied by hemostatic disorders manifesting in coagulopathy (activation of the intrinsic pathway of blood coagulation) and suppression of platelet function. Ceruloplasmin in a total dose of 60 mg/kg effectively normalized coagulation hemostasis and functional activity of platelets by improving secretory processes in platelets and increasing aggregation rate.
Osikov
M V
MV
Department of Pathophysiology, Chelyabinsk State Medical Academy. mvo2003@list.ru
Makarov
E V
EV
Krivokhizhina
L V
LV
D000818:Animals; D001777:Blood Coagulation / Q000187:drug effects; D001792:Blood Platelets / Q000187:drug effects / Q000502:physiology; D002113:Calcification, Physiologic / Q000187:drug effects; D002570:Ceruloplasmin / Q000627:therapeutic use*; D005340:Fibrinogen / Q000378:metabolism; D020141:Hemostatic Disorders / Q000139:chemically induced* / Q000517:prevention & control*; D022124:Hyperammonemia / Q000150:complications*; D008297:Male; D010974:Platelet Aggregation / Q000187:drug effects; D051381:Rats; D013918:Thrombin Time
D005340:Fibrinogen; D002570:Ceruloplasmin